AR060050A1 - Compuestos moduladores del receptor de s1p y uso de los mismos - Google Patents
Compuestos moduladores del receptor de s1p y uso de los mismosInfo
- Publication number
- AR060050A1 AR060050A1 ARP070101166A ARP070101166A AR060050A1 AR 060050 A1 AR060050 A1 AR 060050A1 AR P070101166 A ARP070101166 A AR P070101166A AR P070101166 A ARP070101166 A AR P070101166A AR 060050 A1 AR060050 A1 AR 060050A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- halogen
- substituted
- alkylthio
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 17
- 229910052736 halogen Inorganic materials 0.000 abstract 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 12
- 125000003545 alkoxy group Chemical group 0.000 abstract 12
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 7
- 125000004414 alkyl thio group Chemical group 0.000 abstract 6
- 229910052799 carbon Inorganic materials 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 229910052717 sulfur Inorganic materials 0.000 abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- -1 1H-tetrazol-5-yl Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000005241 heteroarylamino group Chemical group 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuesto, composicion farmacéutica, método para tratar cáncer, enfermedades autoinmunes, diabetes, lupus. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) o sales aceptables para uso farmacéutico del mismo; en donde, p y q son en forma independiente 0, 1, 2, 3 o 4; Z es O, NR2, S, S(O), S(O)2, S(O)2NR2, (CR3R4)n, C=O, C=S, C=N-R2 o un enlace directo; n es 0, 1, 2, 3 o 4; R1 es alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, alcoxi C1-5, arilo o heteroarilo; R2 es hidrogeno, hidroxilo, S(O)2, C=O, C=S, C=NH, alquilo C1-6, alcoxi C1-5, alquiltio C1-5, alquilo C1-6 sustituido con halogeno, alcoxi C1-5 sustituido con halogeno, arilo, o heteroarilo; R3 y R4 son en forma independiente hidrogeno, halo, hidroxilo, ciano, alquilo C1-6, alcoxi C1-5, alquiltio C1-5, alquilo C1-6 sustituido con halogeno, alcoxi C1-5 sustituido con halogeno, arilo, o heteroarilo; o R3 y R4, tomados juntos, pueden formar C=O; X es WC(O)OR5a, WP(O)R5bR5c, WS(O)2OH, WS(O)2NH2, WCONHSO3H o 1H-tetrazol-5-ilo; W es un enlace directo, O o alquileno C1-4 opcionalmente sustituido con uno o más de halo, hidroxilo, ciano, amino, alquilamino, arilamino, heteroarilamino, alcoxi C1-4, o CO2H; R5a es hidrogeno o alquilo C1- 4; R5b y R5c son en forma independiente hidrogeno, hidroxilo, alquilo C1-4, o alquilo C1-4 sustituido con halogeno; Y es un enlace o compuesto del grupo de formulas (2); Q es un enlace directo, C=O, C=S, SO2, C(O)NR9, o (CR9R10)m; m es 0, 1, 2 o 3; R6 y R7 son en forma independiente hidrogeno, halo, hidroxilo, ciano, alquilo C1-6, alquiltio C1-5, alcoxi C1-5, alquilo C1-6 sustituido con halogeno o alcoxi C1-5 sustituido con halogeno; o R6 y R7 puede tomarse junto con los átomos a los cuales están unidos para formar un anillo de 4 a 7 miembros, o R6 es un grupo alquileno con el extremo omega de dicho grupo alquileno unido al anillo A; R8 es hidrogeno, halogeno, hidroxilo, amino, ciano, alquilo C1-6, alquiltio C1-5, alcoxi C1-5, alquilo C1-6 sustituido con halogeno, o alcoxi C1-5 sustituido con halogeno; R9 y R10 son en forma independiente hidrogeno, halo, hidroxilo, ciano, alquilo C1-6, alcoxi C1-5, alquiltio C1-5, alquilo C1-6 sustituido con halogeno, alcoxi C1-5 sustituido con halogeno, o -CO2R5a; A es arilo o heteroarilo, cualquiera de los cuales puede estar opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados del grupo formado por halo, hidroxilo, ciano, alquilo C1-6, alquiltio C1-5, alcoxi C1-5, alquilo C1- 6 sustituido con halogeno, y alcoxi C1-5 sustituido con halogeno; B tiene la formula (3) en el cual, los asteriscos indican el punto de union en la formula (1); n es 1 o 2; U es CH2, C(H)CH3, C(CH3)2, C(H)(CF3), C(CF3)2, o C(=O); y V es C(=O), C(=S), S, S(=O) o S(=O)2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78454806P | 2006-03-21 | 2006-03-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR060050A1 true AR060050A1 (es) | 2008-05-21 |
Family
ID=38421478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070101166A AR060050A1 (es) | 2006-03-21 | 2007-03-21 | Compuestos moduladores del receptor de s1p y uso de los mismos |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7790707B2 (es) |
| EP (1) | EP2010524A2 (es) |
| JP (1) | JP2009530389A (es) |
| AR (1) | AR060050A1 (es) |
| AU (1) | AU2007227274A1 (es) |
| CA (1) | CA2646469A1 (es) |
| CL (1) | CL2007000742A1 (es) |
| TW (1) | TW200806633A (es) |
| WO (1) | WO2007109330A2 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006209216A1 (en) | 2005-01-25 | 2006-08-03 | Galenea Corp | Substituted arylamine compounds and their use as 5-HT6 modulators |
| EP1965807A4 (en) * | 2005-11-23 | 2010-10-27 | Epix Delaware Inc | S1P RECEPTOR MODULATING COMPOUNDS AND THEIR USE |
| US7919519B2 (en) * | 2005-11-23 | 2011-04-05 | Epix Pharmaceuticals Inc. | S1P receptor modulating compounds and use thereof |
| AU2007227274A1 (en) | 2006-03-21 | 2007-09-27 | Epix Delaware, Inc. | S1P receptor modulating compounds |
| US8080542B2 (en) | 2007-09-20 | 2011-12-20 | Amgen, Inc. | S1P receptor modulating compounds and use thereof |
| TW201000099A (en) * | 2008-06-20 | 2010-01-01 | Amgen Inc | S1P1 receptor agonists and use thereof |
| KR20180023049A (ko) | 2008-07-23 | 2018-03-06 | 아레나 파마슈티칼스, 인크. | 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체 |
| EP2342205B1 (en) | 2008-08-27 | 2016-04-20 | Arena Pharmaceuticals, Inc. | Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
| GEP20156250B (en) | 2009-06-26 | 2015-02-25 | Novartis Ag | 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| WO2011059784A1 (en) | 2009-10-29 | 2011-05-19 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds |
| EP4148045A1 (en) | 2010-01-27 | 2023-03-15 | Arena Pharmaceuticals, Inc. | Intermediate compounds for the preparation of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b] indol-3-yl)acetic acid and salts thereof |
| SG10201501575VA (en) | 2010-03-03 | 2015-04-29 | Arena Pharm Inc | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| JP5735634B2 (ja) | 2010-04-23 | 2015-06-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | スフィンゴシン−１−リン酸受容体１アゴニストとしての４−（５−イソオキサゾリルまたは５−ピラゾリル−１，２，４−オキサジアゾール−３−イル）−マンデル酸アミド化合物 |
| ES2539256T3 (es) | 2010-07-20 | 2015-06-29 | Bristol-Myers Squibb Company | Compuestos de 3-fenil-1,2,4-oxadiazol sustituidos |
| ES2548258T3 (es) | 2010-09-24 | 2015-10-15 | Bristol-Myers Squibb Company | Compuestos de oxadiazol sustituidos y su uso como agonistas de S1P1 |
| JP2013544811A (ja) | 2010-11-03 | 2013-12-19 | ブリストル−マイヤーズ スクイブ カンパニー | 自己免疫疾患および血管疾患の治療用のｓ１ｐ１アゴニストとしての複素環式化合物 |
| JP6002210B2 (ja) | 2011-04-28 | 2016-10-05 | ノバルティス アーゲー | １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤 |
| UY35338A (es) | 2013-02-21 | 2014-08-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen |
| TWI689487B (zh) | 2014-08-20 | 2020-04-01 | 美商必治妥美雅史谷比公司 | 經取代雙環化合物 |
| JP6895378B2 (ja) | 2015-01-06 | 2021-06-30 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｓ１ｐ１受容体に関連する状態の処置方法 |
| EP3939965A1 (en) | 2015-06-22 | 2022-01-19 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders |
| EP3507278B1 (en) | 2016-09-02 | 2021-01-27 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
| CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
| WO2018151834A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| WO2019032632A1 (en) | 2017-08-09 | 2019-02-14 | Bristol-Myers Squibb Company | ALKYLPHENYL COMPOUNDS |
| US11059784B2 (en) | 2017-08-09 | 2021-07-13 | Bristol-Myers Squibb Company | Oxime ether compounds |
| KR20210074291A (ko) | 2018-09-06 | 2021-06-21 | 아레나 파마슈티칼스, 인크. | 자가면역 및 염증성 장애의 치료에 유용한 화합물 |
| IL309232A (en) | 2021-06-14 | 2024-02-01 | Scorpion Therapeutics Inc | History of urea which can be used to treat cancer |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3329781A (en) | 1965-07-06 | 1967-07-04 | Mallory & Co Inc P R | Sequential timing device |
| US4767896A (en) | 1985-09-03 | 1988-08-30 | Molex Incorporated | Stamped circuitry assembly |
| ES2087097T3 (es) | 1989-04-19 | 1996-07-16 | Otsuka Pharma Co Ltd | Derivados de acidos fenilcarboxilicos que contienen un heterociclo. |
| SK94393A3 (en) * | 1992-09-11 | 1994-08-10 | Thomae Gmbh Dr K | Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those |
| DE4405378A1 (de) | 1994-02-19 | 1995-08-24 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| JPH10204059A (ja) | 1997-01-22 | 1998-08-04 | Ono Pharmaceut Co Ltd | フェニルスルホンアミド誘導体 |
| JP3802653B2 (ja) | 1997-05-21 | 2006-07-26 | オリンパス株式会社 | 立体画像表示装置 |
| US6384061B1 (en) * | 1997-07-26 | 2002-05-07 | Lg Chemical Ltd. | Hydantoin compounds and methods related thereto |
| EP1383778B1 (en) | 2001-01-30 | 2009-10-21 | University Of Virginia Patent Foundation | Agonists and antagonists of sphingosine-1-phosphate receptors |
| MXPA01013326A (es) | 2001-02-14 | 2002-08-26 | Warner Lambert Co | Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz. |
| US20020183519A1 (en) | 2001-03-13 | 2002-12-05 | Herbert Nar | Antithrombotic carboxylic acid amides |
| CA2472715A1 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Edg receptor agonists |
| US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| AU2003216054B2 (en) | 2002-01-18 | 2007-01-04 | Merck & Co., Inc. | Selective S1P1/Edg1 receptor agonists |
| EP1549640A4 (en) * | 2002-06-17 | 2008-08-06 | Merck & Co Inc | 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATE AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDIN-3-CARBOXYLATE AS EDG RECEPTOR AGONISTS |
| TW200408393A (en) | 2002-10-03 | 2004-06-01 | Ono Pharmaceutical Co | Antagonist of lysophosphatidine acid receptor |
| AU2003298611A1 (en) | 2002-11-21 | 2004-06-18 | Eli Lilly And Company | Mixed lineage kinase modulators |
| DE10300398A1 (de) | 2003-01-09 | 2004-07-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von substituierten 2-Phenylbenzimidazolen als Arzneimittel |
| EP1644367B1 (en) | 2003-05-19 | 2015-10-14 | Novartis AG | Immunosuppressant compounds and compositions |
| CL2004001120A1 (es) | 2003-05-19 | 2005-04-15 | Irm Llc | Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer. |
| EP1698375B1 (en) * | 2003-12-25 | 2014-04-02 | Ono Pharmaceutical Co., Ltd. | Azetidine ring compounds and drugs comprising the same |
| KR20070058455A (ko) | 2004-08-13 | 2007-06-08 | 프래시스 파마슈티컬즈 인코포레이티드 | 스핑고신-1-포스페이트(ｓ1ｐ) 수용체 활성을 조절하기위한 방법 및 조성물 |
| AU2005314938B2 (en) * | 2004-12-13 | 2011-06-09 | Ono Pharmaceutical Co., Ltd. | Aminocarboxylic acid derivative and medicinal use thereof |
| US7919519B2 (en) | 2005-11-23 | 2011-04-05 | Epix Pharmaceuticals Inc. | S1P receptor modulating compounds and use thereof |
| EP1965807A4 (en) | 2005-11-23 | 2010-10-27 | Epix Delaware Inc | S1P RECEPTOR MODULATING COMPOUNDS AND THEIR USE |
| AU2007227274A1 (en) | 2006-03-21 | 2007-09-27 | Epix Delaware, Inc. | S1P receptor modulating compounds |
| AU2007227278B2 (en) | 2007-03-21 | 2014-09-11 | Epix Pharmaceuticals, Inc. | SIP receptor modulating compounds and use thereof |
| US8080542B2 (en) | 2007-09-20 | 2011-12-20 | Amgen, Inc. | S1P receptor modulating compounds and use thereof |
-
2007
- 2007-03-21 AU AU2007227274A patent/AU2007227274A1/en not_active Abandoned
- 2007-03-21 US US11/726,356 patent/US7790707B2/en not_active Expired - Fee Related
- 2007-03-21 JP JP2009501545A patent/JP2009530389A/ja active Pending
- 2007-03-21 AR ARP070101166A patent/AR060050A1/es unknown
- 2007-03-21 TW TW096109748A patent/TW200806633A/zh unknown
- 2007-03-21 CA CA002646469A patent/CA2646469A1/en not_active Abandoned
- 2007-03-21 WO PCT/US2007/007037 patent/WO2007109330A2/en active Application Filing
- 2007-03-21 CL CL2007000742A patent/CL2007000742A1/es unknown
- 2007-03-21 EP EP07753647A patent/EP2010524A2/en not_active Withdrawn
-
2010
- 2010-08-24 US US12/862,631 patent/US20100317649A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2010524A2 (en) | 2009-01-07 |
| JP2009530389A (ja) | 2009-08-27 |
| US20100317649A1 (en) | 2010-12-16 |
| TW200806633A (en) | 2008-02-01 |
| AU2007227274A1 (en) | 2007-09-27 |
| WO2007109330A3 (en) | 2007-11-22 |
| US7790707B2 (en) | 2010-09-07 |
| CA2646469A1 (en) | 2007-09-27 |
| US20080015177A1 (en) | 2008-01-17 |
| CL2007000742A1 (es) | 2008-01-11 |
| WO2007109330A2 (en) | 2007-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR060050A1 (es) | Compuestos moduladores del receptor de s1p y uso de los mismos | |
| PE20221253A1 (es) | Inhibidores de pequenas moleculas de mutante g12c de kras | |
| AR076171A1 (es) | Pirazolopirimidinonas 1,6-disustituidas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento del alzheimer, epilepsia y otras enfermedades del sistema nervioso central. | |
| CO6220949A2 (es) | Derivados pirazolicos como inhibidores de la 11 beta -hsd1 | |
| AR049388A1 (es) | Heterociclos como inhibidores de aldosterona sintasa | |
| PE20060531A1 (es) | Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4 | |
| AR078793A1 (es) | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros | |
| PE20211703A1 (es) | Compuesto derivado heterotriciclico novedoso y uso del mismo | |
| AR054214A1 (es) | Compuestos derivados de 1, 1 - dioxotiadiazina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la infeccion por el virus de la hepatitis c. | |
| AR049125A1 (es) | Heterociclos biciclicos nitrogenados inhibidores de la aromatasa. | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| AR043434A1 (es) | Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos | |
| AR074435A1 (es) | Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer. | |
| AR067996A1 (es) | Derivados heterociclicos de ciclopropano,composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de afecciones asociadas a receptores de histamina h3, tales como enfermedad de alzheimer y esquizofrenia,entre otros. | |
| PE20011166A1 (es) | Piridinas, pirimidinas, purinonas, pirrolopirimidinonas y pirrolopiridinonas como antagonistas del factor liberador de corticotropina | |
| AR045752A1 (es) | Derivados de quinazolina que poseen actividad antitumoral | |
| AR049706A1 (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| AR057987A1 (es) | Compuestos agonistas de cb1 (receptor cannabinoide) | |
| AR049294A1 (es) | DERIVADOS DE QUINAZOLINA; INHIBIDORES DE LA TIROSINA QUINASA DEL RECEPTOR ERBB2; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN; MÉTODOS PARA SU PREPARACIoN Y SU USO COMO MEDICAMENTO PARA EL TRATAMIENTO O PREVENCIoN DE TUMORES SoLIDOS. | |
| AR044011A1 (es) | Antagonistas de mchr1 heterociclicos | |
| AR065583A1 (es) | Compuestos macrociclicos y composicion farmaceutica | |
| ES2452299T3 (es) | Compuestos heterocíclicos fungicidas | |
| PE20170775A1 (es) | Derivados de benzodiazepina citotoxicos | |
| BRPI0519288A2 (pt) | compostos heterocÍclicos como antagonistas de ccr2b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |